Amendment AA3-AB69

LRBa0043/1

MED:jld

2017 - 2018 LEGISLATURE

ASSEMBLY AMENDMENT 3, TO ASSEMBLY BILL 69

February 28, 2017 - Offered by Representatives Subeck, Kolste, C. Taylor and Zamarripa.

AB69-AA3,1,1 At the locations indicated, amend the bill as follows:

AB69-AA3,1,2 1. Page 3, line 10: after “Manufacturers." insert “(a)".

AB69-AA3,1,3 2. Page 3, line 12: after “patient." insert:

AB69-AA3,1,4 “(b)".

AB69-AA3,1,5 3. Page 3, line 16: after that line insert:

AB69-AA3,1,12 “(c) During the time an eligible patient is using an investigational drug, device, or biological product as provided in this section, the manufacturer shall notify the treating physician and the eligible patient of any clinically significant finding of a known or anticipated risk, side effect, or reported patient discomfort that is likely related to the investigational drug, device, or biological product that becomes known to the manufacturer after the eligible patient begins using the investigational drug, device, or biological product.”.

AB69-AA3,1,13 (End)